2‐Thioxo‐3,4‐dihydropyrimidine and thiourea endowed with sulfonamide moieties as dual EGFR^T790M and VEGFR‐2 inhibitors: Design, synthesis, docking, and anticancer evaluations

Abstract

Abstract The effectiveness of a new series of thiopyrimidine and thiourea containing sulfonamides moieties was tested on HCT‐116, MCF‐7, HepG2, and A549. HepG2 cell line was the one that all the new derivatives affected the most. The greatest potent compounds against the four HepG2, HCT116, MCF‐7, and A549 cell lines were 8f and 8g with IC 50 = 4.13, 6.64, 5.74, 6.85 µM and 4.09, 4.36, 4.22, 7.25 µM correspondingly. Compound 8g exhibited higher activity than sorafenib against HCT116 and MCF‐7 but exhibited lower activity against HepG2 and A549. Moreover, compounds 8f and 8g exhibited higher activities than erlotinib on HepG2, HCT116, and MCF‐7 but demonstrated lower activity on A549. The most potent cytotoxic derivatives 6f , 6g , 8c , 8d, 8e, 8f , and 8g were examined on normal VERO cell lines. Our derivatives have low toxicity on VERO cells with IC 50 values ranging from 32.05 to 53.15 μM. Additionally, all compounds were assessed for dual VEGFR‐2 and EGFR T790M inhibition effects. Compounds 8f and 8g were the most potent derivatives inhibited VEGFR‐2 at IC 50 value of 0.88 and 0.90 µM, correspondingly. As well, derivatives 8f and 8g could inhibit EGFR T790M demonstrating strongest effects with IC 50 = 0.32 and 0.33 µM sequentially. Additionally, the greatest active derivatives ADMET profile was evaluated in relationship with sorafenib and erlotinib as reference agents. The data attained from docking were greatly related to that achieved from the biological testing.